Discover the future of heart failure treatment
DRG Disease Landscape & Forecast
The Heart failure – Disease Landscape & Forecast (G7) report delivers in-depth intelligence on market dynamics, emerging therapies, and 10-year sales forecasts across acute heart failure (AHF) and chronic heart failure (CHF). With expert insights, real-time pipeline intelligence from Cortellis, and primary research from 27 leading cardiologists, this report provides the strategic foresight needed to navigate this evolving market.
Request more information
Key trends in heart failure treatment:
SGLT-2 Inhibitors are becoming the standard of care
-
Jardiance (Eli Lilly/Boehringer Ingelheim) and Farxiga (AstraZeneca) are now core treatments across HFrEF and HFpEF.
-
The role of SGLT-2 inhibitors is expanding beyond ejection fraction classifications.
New therapies for HFpEF are on the horizon
-
Semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) are poised to reshape HFpEF treatment.
-
Other pipeline therapies, including Bayer’s finerenone and AstraZeneca’s balcinrenone/dapagliflozin FDC, aim to address unmet needs in heart failure management.
Market expansion expected through 2033
-
The heart failure therapy market will continue to grow, driven by branded drug uptake, new approvals, and increasing prevalence.
-
Emerging therapies are expected to improve outcomes while competing for market share in a crowded space.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
-
How large are the treatable AHF, HFrEF, and HFpEF populations, and how will diagnosis rates change over time?
-
What are the drivers and constraints in the heart failure therapy market, and how will the market evolve through 2033?
-
Which emerging therapies generate the most enthusiasm among thought leaders, and what is the expected level of market penetration?
-
How will the treatment of HFpEF evolve following the launches of semaglutide and tirzepatide?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
10-year market forecast (2023–2033)
Annualized drug-level sales and patient share projections across the U.S., EU5, and Japan.
Global Epidemiology & Market segmentation
Diagnosed and drug-treated cases of acute and chronic heart failure, segmented by ejection fraction (HFrEF C HFpEF).
Pipeline Intelligence Powered by Cortellis
Real-time updates on current and emerging therapies, including novel drug classes.
Primary research with 27 thought-leading cardiologists
Expert perspectives on treatment adoption, unmet needs, and future opportunities.
What is Disease Landscape & Forecast?
Disease Landscape & Forecast is a premier market intelligence platform, offering:
-
Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts
-
Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year
-
Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis
Expert insights on heart failure
Built on expert knowledge and rigorous research
-
27 expert interviews with leading cardiologists across the G7.
-
Comprehensive epidemiological modeling for heart failure subpopulations.
-
Real-time pipeline intelligence tracking the most promising therapies.
